Cargando…

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

INTRODUCTION: Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis of the skin and internal organs. We sought to assess the clinical and molecular effects associated with response to intravenous abatacept in patients with diffuse cutaneous systemic. METHODS: Adult d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakravarty, Eliza F., Martyanov, Viktor, Fiorentino, David, Wood, Tammara A., Haddon, David James, Jarrell, Justin Ansel, Utz, Paul J., Genovese, Mark C., Whitfield, Michael L., Chung, Lorinda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487200/ https://www.ncbi.nlm.nih.gov/pubmed/26071192 http://dx.doi.org/10.1186/s13075-015-0669-3

Ejemplares similares

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
por: Gordon, Jessica K., et al.
Publicado: (2015)

Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation
por: Mehta, Bhaven K., et al.
Publicado: (2022)

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature
por: Derrett-Smith, Emma C., et al.
Publicado: (2017)

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms
por: Mahoney, J. Matthew, et al.
Publicado: (2015)

Identification of cell cycle–regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors
por: Grant, Gavin D., et al.
Publicado: (2013)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Behçet’s disease
por: Maciel, Marcus de Luca, et al.
Publicado: (2017)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis
por: Arron, Sarah T., et al.
Publicado: (2014)

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
por: Taroni, Jaclyn N., et al.
Publicado: (2017)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Demonstration of Cutaneous Allodynia in Association with Chronic Pelvic Pain
por: Jarrell, John
Publicado: (2009)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis
por: Hinchcliff, Monique, et al.
Publicado: (2013)

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
por: Arefiev, Kait, et al.
Publicado: (2011)

Clinical Presentation and Evaluation of Dermatomyositis
por: Marvi, Umaima, et al.
Publicado: (2012)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Correction to: Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination
por: Cole, Alice, et al.
Publicado: (2022)

Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures
por: Taroni, Jaclyn N., et al.
Publicado: (2015)

Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
por: Matsubara, Tsukasa, et al.
Publicado: (2018)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n6aovo6ghm85cu2gqn2qtergdd